C4 Therapeutics projects funding will last until the end of 2028.
Cash Position Overview: As of September 30, 2025, the company had $199.8 million in cash, cash equivalents, and marketable securities, down from $223.0 million in June 2025 and $267.3 million in December 2024.
Reasons for Decrease: The decline in cash reserves during the third quarter was mainly due to operational funding and program advancements, partially offset by $7.5 million from an equity program.
Equity Offering Impact: The reported cash figures do not include $125 million raised from an equity offering in October 2025.
Future Funding Outlook: The company anticipates that its current cash and equivalents will support its operational plans through the end of 2028.
Trade with 70% Backtested Accuracy
Analyst Views on CCCC
About CCCC
About the author
C4 Therapeutics to Initiate Two Cemsidomide Trials in 2026
- Clinical Trial Progress: C4 Therapeutics plans to initiate the Phase 2 MOMENTUM trial of cemsidomide in Q1 2026, with enrollment expected to complete within 12 months, aiming to provide new treatment options for relapsed/refractory multiple myeloma patients, thereby solidifying its position in oncology drug development.
- Combination Therapy Research: A Phase 1b trial combining cemsidomide with elranatamab is set to begin in Q2 2026, exploring its potential in multiple myeloma treatment, which is expected to offer more therapeutic options for patients and enhance the company's competitiveness in this field.
- Funding Assurance: C4 Therapeutics anticipates a cash runway extending to the end of 2028, providing financial support through key value inflection points, ensuring smooth progression of clinical trials and drug development.
- Internal Discovery Strategy: The company is advancing a new discovery strategy focused on inflammation, neuro-inflammation, and neuro-degenerative diseases, with plans to submit up to three investigational new drug applications by the end of 2028, demonstrating its strong capabilities and market potential in innovative drug development.
Most Active Stocks After Hours on December 18, 2025: BAC, C, NVDA, CCCC, GRAB, RXRX, AAPL, QQQ, COMP, PCG, PGRE, NU
NASDAQ 100 After Hours Performance: The NASDAQ 100 After Hours Indicator is down by 39.83 points, closing at 24,979.54, with a total after-hours trading volume of 182,940,691 shares.
Active Stocks Overview: Notable active stocks include Bank of America (BAC) down slightly, Citigroup (C) unchanged, and NVIDIA (NVDA) also down, with all three having a mean recommendation in the "buy range."
Stock Recommendations: Other stocks like C4 Therapeutics (CCCC), Grab Holdings (GRAB), and Apple (AAPL) are also highlighted, with their current mean recommendations indicating a "buy" sentiment.
Market Insights: The article emphasizes that the views expressed are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Coca-Cola Femsa Analyst Changes Stance; Discover Tuesday's Two Major Downgrades
Analyst Downgrades: Barclays analyst Benjamin Theurer downgraded Coca-Cola Femsa SAB de CV from Overweight to Equal-Weight, maintaining a price target of $98, while shares closed at $87.60.
10x Genomics Rating Change: Morgan Stanley analyst Tejas Savant downgraded 10x Genomics, Inc. from Overweight to Equal-Weight, raising the price target from $17 to $20, with shares closing at $18.08.
Market Overview: The article provides a snapshot of various stocks, including Coca-Cola Femsa and 10x Genomics, along with their recent performance and analyst ratings.
Investment Advice Disclaimer: The content is sourced from Benzinga, which does not provide investment advice and emphasizes the importance of consulting analysts for stock evaluations.
Cloudflare Analyst Starts Coverage Optimistically; Check Out Tuesday's Top 5 Initiations
Analyst Ratings Initiations: Several Wall Street analysts have initiated coverage on various companies, providing new ratings and price targets for investors to consider.
Blackline Inc: Rosenblatt analyst Robert Simmons initiated coverage with a Buy rating and a price target of $65, while the stock closed at $56.09.
C4 Therapeutics Inc: TD Cowen analyst Tyler Van Buren also initiated coverage with a Buy rating, with shares closing at $2.54.
Cloudflare Inc and Others: Barclays analyst Saket Kalia gave Cloudflare an Overweight rating with a price target of $235, while UBS and Wells Fargo analysts provided ratings for Weatherford International and California Resources, respectively.
C4 Therapeutics Launches $400 Million Mixed Shelf Offering
Shelf Registration Filing: C4 Therapeutics has filed a shelf registration to offer up to $400 million in various securities, including common stock, preferred stock, debt securities, warrants, or units.
Recent Offerings and Presentations: The company recently priced a $125 million equity offering with warrants and has presented data on its Phase 1 trial of Cemsidomide in multiple myeloma at the IMS Annual Meeting 2025.
Precision Oncology Approaches Drive $312B Market Transformation
Advancements in Oncology: Biomarker-driven drug development is accelerating in oncology, with companies achieving high response rates in targeted patient subgroups and the FDA expediting reviews for innovative therapies. Multi-cancer early detection blood tests are also showing promise, identifying two-thirds of cancers with a single draw.
GT Biopharma's Clinical Trials: GT Biopharma is progressing in its Phase 1 clinical trial of GTB-3650 for treating relapsed or refractory blood cancers, with encouraging early results indicating immune activation. The company plans to file for human trials of another candidate, GTB-5550, targeting solid tumors by late 2025.
C4 Therapeutics to Initiate Two Cemsidomide Trials in 2026
- Clinical Trial Progress: C4 Therapeutics plans to initiate the Phase 2 MOMENTUM trial of cemsidomide in Q1 2026, with enrollment expected to complete within 12 months, aiming to provide new treatment options for relapsed/refractory multiple myeloma patients, thereby solidifying its position in oncology drug development.
- Combination Therapy Research: A Phase 1b trial combining cemsidomide with elranatamab is set to begin in Q2 2026, exploring its potential in multiple myeloma treatment, which is expected to offer more therapeutic options for patients and enhance the company's competitiveness in this field.
- Funding Assurance: C4 Therapeutics anticipates a cash runway extending to the end of 2028, providing financial support through key value inflection points, ensuring smooth progression of clinical trials and drug development.
- Internal Discovery Strategy: The company is advancing a new discovery strategy focused on inflammation, neuro-inflammation, and neuro-degenerative diseases, with plans to submit up to three investigational new drug applications by the end of 2028, demonstrating its strong capabilities and market potential in innovative drug development.
Most Active Stocks After Hours on December 18, 2025: BAC, C, NVDA, CCCC, GRAB, RXRX, AAPL, QQQ, COMP, PCG, PGRE, NU
NASDAQ 100 After Hours Performance: The NASDAQ 100 After Hours Indicator is down by 39.83 points, closing at 24,979.54, with a total after-hours trading volume of 182,940,691 shares.
Active Stocks Overview: Notable active stocks include Bank of America (BAC) down slightly, Citigroup (C) unchanged, and NVIDIA (NVDA) also down, with all three having a mean recommendation in the "buy range."
Stock Recommendations: Other stocks like C4 Therapeutics (CCCC), Grab Holdings (GRAB), and Apple (AAPL) are also highlighted, with their current mean recommendations indicating a "buy" sentiment.
Market Insights: The article emphasizes that the views expressed are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Coca-Cola Femsa Analyst Changes Stance; Discover Tuesday's Two Major Downgrades
Analyst Downgrades: Barclays analyst Benjamin Theurer downgraded Coca-Cola Femsa SAB de CV from Overweight to Equal-Weight, maintaining a price target of $98, while shares closed at $87.60.
10x Genomics Rating Change: Morgan Stanley analyst Tejas Savant downgraded 10x Genomics, Inc. from Overweight to Equal-Weight, raising the price target from $17 to $20, with shares closing at $18.08.
Market Overview: The article provides a snapshot of various stocks, including Coca-Cola Femsa and 10x Genomics, along with their recent performance and analyst ratings.
Investment Advice Disclaimer: The content is sourced from Benzinga, which does not provide investment advice and emphasizes the importance of consulting analysts for stock evaluations.
Cloudflare Analyst Starts Coverage Optimistically; Check Out Tuesday's Top 5 Initiations
Analyst Ratings Initiations: Several Wall Street analysts have initiated coverage on various companies, providing new ratings and price targets for investors to consider.
Blackline Inc: Rosenblatt analyst Robert Simmons initiated coverage with a Buy rating and a price target of $65, while the stock closed at $56.09.
C4 Therapeutics Inc: TD Cowen analyst Tyler Van Buren also initiated coverage with a Buy rating, with shares closing at $2.54.
Cloudflare Inc and Others: Barclays analyst Saket Kalia gave Cloudflare an Overweight rating with a price target of $235, while UBS and Wells Fargo analysts provided ratings for Weatherford International and California Resources, respectively.
C4 Therapeutics Launches $400 Million Mixed Shelf Offering
Shelf Registration Filing: C4 Therapeutics has filed a shelf registration to offer up to $400 million in various securities, including common stock, preferred stock, debt securities, warrants, or units.
Recent Offerings and Presentations: The company recently priced a $125 million equity offering with warrants and has presented data on its Phase 1 trial of Cemsidomide in multiple myeloma at the IMS Annual Meeting 2025.
Precision Oncology Approaches Drive $312B Market Transformation
Advancements in Oncology: Biomarker-driven drug development is accelerating in oncology, with companies achieving high response rates in targeted patient subgroups and the FDA expediting reviews for innovative therapies. Multi-cancer early detection blood tests are also showing promise, identifying two-thirds of cancers with a single draw.
GT Biopharma's Clinical Trials: GT Biopharma is progressing in its Phase 1 clinical trial of GTB-3650 for treating relapsed or refractory blood cancers, with encouraging early results indicating immune activation. The company plans to file for human trials of another candidate, GTB-5550, targeting solid tumors by late 2025.
